Merck Will No Longer Be ‘Easy to Own’ on Keytruda Dominance

(Bloomberg) -- Merck & Co.’s plan to spin off its women’s health and biosimilar medicines units is sparking debate about its dependence on its top-selling drug among Wall Street analysts.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.